View ValuationVitrolife 향후 성장Future 기준 점검 3/6Vitrolife (는) 각각 연간 103.8% 및 6.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 103.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.2% 로 예상됩니다.핵심 정보103.8%이익 성장률103.78%EPS 성장률Biotechs 이익 성장23.2%매출 성장률6.6%향후 자기자본이익률7.23%애널리스트 커버리지Low마지막 업데이트30 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 29+ 3 more updatesVitrolife AB (publ) to Report Q2, 2027 Results on Jul 16, 2027Vitrolife AB (publ) announced that they will report Q2, 2027 results on Jul 16, 2027Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Karen Sorensen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 07+ 1 more updateVitrolife AB (publ) Approves Dividend, Payable on 12 May 2026Vitrolife AB (publ) at its Annual General Meeting held on May 5, 2026, resolved to distribute a dividend of SEK 1.10 per share. The record date for the dividend is 7 May 2026. Payment is expected to be made on 12 May 2026.공시 • Feb 03+ 2 more updatesVitrolife AB (publ), Annual General Meeting, May 05, 2026Vitrolife AB (publ), Annual General Meeting, May 05, 2026. Location: gothenburg Sweden공시 • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026공시 • Apr 29Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.공시 • Apr 10Vitrolife AB (publ) Announces CFO ChangesVitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office.공시 • Mar 31Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp InnovationVitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson.공시 • Feb 21The Vitrolife Group Appoints Ermanno Sironi as Chief Operating OfficerThe Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.공시 • Jan 31Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden공시 • Jan 30Vitrolife AB (Publ) Proposes DividendThe Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.공시 • Dec 03Vitrolife AB (Publ) Announces Chief Financial Officer ChangesVitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.공시 • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025공시 • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)Third quarter 2024 results: EPS: kr0.86 (down from kr0.90 in 3Q 2023). Revenue: kr867.0m (up 2.2% from 3Q 2023). Net income: kr116.0m (down 4.9% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.공시 • Oct 04Vitrolife AB (Publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.Buy Or Sell Opportunity • Sep 27Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to €21.32. The fair value is estimated to be €17.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Sep 02Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to €21.94. The fair value is estimated to be €18.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company became loss making.공시 • Jul 24+ 2 more updatesVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)Second quarter 2024 results: EPS: kr1.06 (up from kr0.78 in 2Q 2023). Revenue: kr941.0m (up 4.0% from 2Q 2023). Net income: kr143.0m (up 35% from 2Q 2023). Profit margin: 15% (up from 12% in 2Q 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.Buy Or Sell Opportunity • Jul 05Now 19% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.2% to €14.91. The fair value is estimated to be €18.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jul 04Now 19% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.7% to €14.83. The fair value is estimated to be €18.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jul 03Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.0% to €14.91. The fair value is estimated to be €18.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.공시 • May 23Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million.공시 • May 03Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.공시 • Apr 27Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day.Upcoming Dividend • Apr 21Upcoming dividend of kr1.00 per shareEligible shareholders must have bought the stock before 26 April 2024. Payment date: 03 May 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (1.8%).Buy Or Sell Opportunity • Apr 19Now 24% undervaluedThe stock has been flat over the last 90 days, currently trading at €14.18. The fair value is estimated to be €18.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Apr 18First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)First quarter 2024 results: EPS: kr0.85 (up from kr0.74 in 1Q 2023). Revenue: kr841.0m (down 1.5% from 1Q 2023). Net income: kr115.0m (up 15% from 1Q 2023). Profit margin: 14% (up from 12% in 1Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.Declared Dividend • Apr 07Dividend of kr1.00 announcedShareholders will receive a dividend of kr1.00. Ex-date: 26th April 2024 Payment date: 3rd May 2024 Dividend yield will be 6.4%, which is higher than the industry average of 2.8%.Reported Earnings • Feb 03Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)Full year 2023 results: kr28.44 loss per share (down from kr2.91 profit in FY 2022). Revenue: kr3.51b (up 8.6% from FY 2022). Net loss: kr3.85b (down kr4.25b from profit in FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.공시 • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024공시 • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.Buying Opportunity • Nov 14Now 20% undervaluedOver the last 90 days, the stock is up 5.6%. The fair value is estimated to be €16.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 19% in 2 years. Earnings is forecast to grow by 87% in the next 2 years.Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)Third quarter 2023 results: EPS: kr0.90 (up from kr0.80 in 3Q 2022). Revenue: kr848.0m (up 6.3% from 3Q 2022). Net income: kr122.0m (up 13% from 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.공시 • Oct 06Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board.공시 • Aug 24Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice PresidentVitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017.Board Change • Aug 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Sorensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 01Vitrolife AB Announces Board ChangesVitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.Valuation Update With 7 Day Price Move • Jul 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €13.87, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.15 per share.New Risk • Jul 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Jul 14Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)Second quarter 2023 results: EPS: kr0.78 (down from kr0.96 in 2Q 2022). Revenue: kr905.0m (up 9.2% from 2Q 2022). Net income: kr106.0m (down 19% from 2Q 2022). Profit margin: 12% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.공시 • Jul 14+ 4 more updatesVitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vitrolife AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €20.88, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 4.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.55 per share.Recent Insider Transactions • May 04Chief Financial Officer recently bought €47k worth of stockOn the 26th of April, Patrik Tolf bought around 3k shares on-market at roughly €18.78 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of €96k worth in shares.Upcoming Dividend • Apr 21Upcoming dividend of kr0.85 per share at 0.4% yieldEligible shareholders must have bought the stock before 28 April 2023. Payment date: 05 May 2023. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.5%).Reported Earnings • Apr 02Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)Full year 2022 results: EPS: kr2.91. Revenue: kr3.23b (up 92% from FY 2021). Net income: kr394.0m (up 16% from FY 2021). Profit margin: 12% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Launched (during full year): 2 Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Germany.Reported Earnings • Feb 04Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)Full year 2022 results: EPS: kr2.91. Revenue: kr3.23b (up 92% from FY 2021). Net income: kr394.0m (up 16% from FY 2021). Profit margin: 12% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe.공시 • Feb 02+ 1 more updateVitrolife AB (publ) Proposes Dividend for 2022Vitrolife AB (publ) proposed a dividend of SEK 0.85 per share for 2022 compared to SEK 0.80 per share a year ago, corresponding to SEK 115 million (SEK 108 million a year ago).공시 • Feb 01Vitrolife AB (publ) Announces Executive ChangesVitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021)Third quarter 2022 results: EPS: kr0.80. Revenue: kr798.0m (up 97% from 3Q 2021). Net income: kr108.0m (up 3.5% from 3Q 2021). Profit margin: 14% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.공시 • Oct 27+ 3 more updatesVitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023Vitrolife AB (publ) announced that they will report first half, 2023 results on Jul 14, 2023공시 • Oct 11Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced that the following people have been appointed as members of Vitrolife's election committee for the Annual General Meeting in 2023: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Erika Henriksson, appointed by EQT VIII; and Jón Sigurdsson, Chairman of the Board.Valuation Update With 7 Day Price Move • Sep 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €17.23, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 26x in the Biotechs industry in Europe. Total returns to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.53 per share.Buying Opportunity • Sep 23Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.7%. The fair value is estimated to be €23.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 4.2%. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 105% in the next 2 years.공시 • Sep 13Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEOVitrolife AB (publ) announced that Thomas Axelsson, CEO of the company informed the Board of Directors of his desire and intention to retire and be released from his position. Consequently, the process to find a new CEO to replace Thomas will immediately begin and will be led by Jon Sigurdsson, Chairman of the Board. Thomas will remain as the CEO until the recruitment process is finalized.Reported Earnings • Jul 17Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)Second quarter 2022 results: EPS: kr0.96 (up from kr0.79 in 2Q 2021). Revenue: kr829.0m (up 117% from 2Q 2021). Net income: kr130.0m (up 51% from 2Q 2021). Profit margin: 16% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 37%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.공시 • Jul 08Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023.Recent Insider Transactions • May 04Chief Financial Officer recently bought €48k worth of stockOn the 29th of April, Patrik Tolf bought around 2k shares on-market at roughly €23.97 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)First quarter 2022 results: EPS: kr0.61 (down from kr1.09 in 1Q 2021). Revenue: kr752.0m (up 98% from 1Q 2021). Net income: kr82.0m (down 31% from 1Q 2021). Profit margin: 11% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 56%, compared to a 43% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Apr 23First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)First quarter 2022 results: EPS: kr0.61 (down from kr1.09 in 1Q 2021). Revenue: kr752.0m (up 98% from 1Q 2021). Net income: kr82.0m (down 31% from 1Q 2021). Profit margin: 11% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 58%, compared to a 46% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Upcoming Dividend • Apr 21Upcoming dividend of kr0.80 per shareEligible shareholders must have bought the stock before 28 April 2022. Payment date: 04 May 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.9%). Lower than average of industry peers (1.4%).공시 • Mar 29Vitrolife AB (Publ) Proposes DividendThe Board of Directors of Vitrolife AB (publ) proposed a dividend of SEK 0.80 per share and 29 April 2022 as the record day for the dividend, to its Annual General Meeting to be held on April 27, 2022.Reported Earnings • Feb 17Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: kr2.97 (up from kr2.64 in FY 2020). Revenue: kr1.68b (up 35% from FY 2020). Net income: kr341.0m (up 19% from FY 2020). Profit margin: 20% (down from 23% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 94%, compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 16Vitrolife AB (Publ) Proposes DividendVitrolife AB (publ) proposed a dividend of SEK 108 million, corresponding to SEK 0.80 per share, compared to SEK 0.80 per share a year ago.Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: kr405.6m (up 27% from 3Q 2020). Net income: kr104.3m (up 18% from 3Q 2020). Profit margin: 26% (down from 28% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 17Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr382.0m (up 83% from 2Q 2020). Net income: kr85.8m (up kr74.2m from 2Q 2020). Profit margin: 23% (up from 5.6% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.공시 • Apr 29Vitrolife AB (publ) Approves Dividend for the Financial Year 2020At the Vitrolife AB (publ)’s Annual General Meeting held on April 28, 2021, the company approved dividend of SEK 0.80 per share for the financial year 2020. April 30, 2021 was adopted as the record day.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr379.0m (up 14% from 1Q 2020). Net income: kr118.2m (up 48% from 1Q 2020). Profit margin: 31% (up from 24% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Apr 22Upcoming dividend of kr0.80 per shareEligible shareholders must have bought the stock before 29 April 2021. Payment date: 05 May 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.5%).Reported Earnings • Apr 01Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr1.25b (down 16% from FY 2019). Net income: kr286.8m (down 25% from FY 2019). Profit margin: 23% (down from 26% in FY 2019). The decrease in margin was driven by lower revenue. Post-clinical trial products Launched (during full year): 2 Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Feb 12Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr1.25b (down 16% from FY 2019). Net income: kr286.8m (down 25% from FY 2019). Profit margin: 23% (down from 26% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Feb 12Revenue misses expectationsRevenue missed analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 18%, compared to a 80% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Feb 03New 90-day high: €22.60The company is up 2.0% from its price of €22.20 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.49 per share.공시 • Jan 22Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021Vitrolife AB (publ) announced that they will report fiscal year 2020 results at 8:00 AM, Central European Standard Time on Feb 10, 2021Is New 90 Day High Low • Nov 16New 90-day low: €20.14The company is down 10.0% from its price of €22.46 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.55 per share.Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS kr0.81The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: kr320.1m (down 15% from 3Q 2019). Net income: kr88.2m (down 17% from 3Q 2019). Profit margin: 28% (in line with 3Q 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectationsRevenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 12%, compared to a 321% growth forecast for the Biotechs industry in Germany.공시 • Nov 07Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021Vitrolife AB (publ) announced that they will report fiscal year 2020 results at 6:46 AM, GMT Standard Time on Mar 30, 2021공시 • Nov 06Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021Vitrolife AB (publ) announced that they will report Q1, 2021 results at 6:46 AM, GMT Standard Time on Apr 22, 2021이익 및 매출 성장 예측DB:VTFN - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,0557037841,040512/31/20273,776600709948512/31/20263,50148060983253/31/20263,405-5,011486738N/A12/31/20253,440-5,012388635N/A9/30/20253,507440468742N/A6/30/20253,541455429693N/A3/31/20253,610498575778N/A12/31/20243,609513705907N/A9/30/20243,555-3,805649811N/A6/30/20243,535-3,799671819N/A3/31/20243,499-3,836655795N/A12/31/20233,512-3,851638757N/A9/30/20233,462402650752N/A6/30/20233,412388652738N/A3/31/20233,336412631706N/A12/31/20223,234394549636N/A9/30/20222,893353366470N/A6/30/20222,501349288377N/A3/31/20222,054305249331N/A12/31/20211,681341321384N/A9/30/20211,549415525555N/A6/30/20211,464399515545N/A3/31/20211,291325455479N/A12/31/20201,246287336356N/A9/30/20201,273276278303N/A6/30/20201,331294332361N/A3/31/20201,502377315399N/A12/31/20191,480383N/A413N/A9/30/20191,391371N/A412N/A6/30/20191,297339N/A344N/A3/31/20191,199324N/A341N/A12/31/20181,151310N/A349N/A9/30/20181,102294N/A343N/A6/30/20181,064284N/A341N/A3/31/20181,066276N/A321N/A12/31/20171,046264N/A312N/A9/30/20171,026255N/A281N/A6/30/2017991234N/A243N/A3/31/2017913211N/A204N/A12/31/2016856190N/A181N/A9/30/2016804188N/A197N/A6/30/2016771196N/A210N/A3/31/2016747186N/A196N/A12/31/2015722183N/A194N/A9/30/2015660154N/A138N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VTFN 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: VTFN (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: VTFN 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: VTFN 의 수익(연간 6.6%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: VTFN 의 수익(연간 6.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VTFN의 자본 수익률은 3년 후 7.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 12:06종가2026/06/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vitrolife AB (publ)는 11명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierKallum TitchmarshBofA Global ResearchKristofer Liljeberg-SvenssonCarnegie Investment Bank AB8명의 분석가 더 보기
공시 • May 29+ 3 more updatesVitrolife AB (publ) to Report Q2, 2027 Results on Jul 16, 2027Vitrolife AB (publ) announced that they will report Q2, 2027 results on Jul 16, 2027
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Karen Sorensen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 07+ 1 more updateVitrolife AB (publ) Approves Dividend, Payable on 12 May 2026Vitrolife AB (publ) at its Annual General Meeting held on May 5, 2026, resolved to distribute a dividend of SEK 1.10 per share. The record date for the dividend is 7 May 2026. Payment is expected to be made on 12 May 2026.
공시 • Feb 03+ 2 more updatesVitrolife AB (publ), Annual General Meeting, May 05, 2026Vitrolife AB (publ), Annual General Meeting, May 05, 2026. Location: gothenburg Sweden
공시 • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
공시 • Apr 29Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
공시 • Apr 10Vitrolife AB (publ) Announces CFO ChangesVitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office.
공시 • Mar 31Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp InnovationVitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson.
공시 • Feb 21The Vitrolife Group Appoints Ermanno Sironi as Chief Operating OfficerThe Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.
공시 • Jan 31Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden
공시 • Jan 30Vitrolife AB (Publ) Proposes DividendThe Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.
공시 • Dec 03Vitrolife AB (Publ) Announces Chief Financial Officer ChangesVitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.
공시 • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025
공시 • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)Third quarter 2024 results: EPS: kr0.86 (down from kr0.90 in 3Q 2023). Revenue: kr867.0m (up 2.2% from 3Q 2023). Net income: kr116.0m (down 4.9% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
공시 • Oct 04Vitrolife AB (Publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.
Buy Or Sell Opportunity • Sep 27Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to €21.32. The fair value is estimated to be €17.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Sep 02Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to €21.94. The fair value is estimated to be €18.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company became loss making.
공시 • Jul 24+ 2 more updatesVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025
Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)Second quarter 2024 results: EPS: kr1.06 (up from kr0.78 in 2Q 2023). Revenue: kr941.0m (up 4.0% from 2Q 2023). Net income: kr143.0m (up 35% from 2Q 2023). Profit margin: 15% (up from 12% in 2Q 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.
Buy Or Sell Opportunity • Jul 05Now 19% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.2% to €14.91. The fair value is estimated to be €18.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jul 04Now 19% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.7% to €14.83. The fair value is estimated to be €18.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jul 03Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.0% to €14.91. The fair value is estimated to be €18.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.
공시 • May 23Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million.
공시 • May 03Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.
공시 • Apr 27Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day.
Upcoming Dividend • Apr 21Upcoming dividend of kr1.00 per shareEligible shareholders must have bought the stock before 26 April 2024. Payment date: 03 May 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (1.8%).
Buy Or Sell Opportunity • Apr 19Now 24% undervaluedThe stock has been flat over the last 90 days, currently trading at €14.18. The fair value is estimated to be €18.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Apr 18First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)First quarter 2024 results: EPS: kr0.85 (up from kr0.74 in 1Q 2023). Revenue: kr841.0m (down 1.5% from 1Q 2023). Net income: kr115.0m (up 15% from 1Q 2023). Profit margin: 14% (up from 12% in 1Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.
Declared Dividend • Apr 07Dividend of kr1.00 announcedShareholders will receive a dividend of kr1.00. Ex-date: 26th April 2024 Payment date: 3rd May 2024 Dividend yield will be 6.4%, which is higher than the industry average of 2.8%.
Reported Earnings • Feb 03Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)Full year 2023 results: kr28.44 loss per share (down from kr2.91 profit in FY 2022). Revenue: kr3.51b (up 8.6% from FY 2022). Net loss: kr3.85b (down kr4.25b from profit in FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
공시 • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
공시 • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.
Buying Opportunity • Nov 14Now 20% undervaluedOver the last 90 days, the stock is up 5.6%. The fair value is estimated to be €16.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 19% in 2 years. Earnings is forecast to grow by 87% in the next 2 years.
Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)Third quarter 2023 results: EPS: kr0.90 (up from kr0.80 in 3Q 2022). Revenue: kr848.0m (up 6.3% from 3Q 2022). Net income: kr122.0m (up 13% from 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
공시 • Oct 06Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board.
공시 • Aug 24Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice PresidentVitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017.
Board Change • Aug 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Karen Sorensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 01Vitrolife AB Announces Board ChangesVitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €13.87, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.15 per share.
New Risk • Jul 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Jul 14Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)Second quarter 2023 results: EPS: kr0.78 (down from kr0.96 in 2Q 2022). Revenue: kr905.0m (up 9.2% from 2Q 2022). Net income: kr106.0m (down 19% from 2Q 2022). Profit margin: 12% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
공시 • Jul 14+ 4 more updatesVitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vitrolife AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €20.88, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 4.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.55 per share.
Recent Insider Transactions • May 04Chief Financial Officer recently bought €47k worth of stockOn the 26th of April, Patrik Tolf bought around 3k shares on-market at roughly €18.78 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of €96k worth in shares.
Upcoming Dividend • Apr 21Upcoming dividend of kr0.85 per share at 0.4% yieldEligible shareholders must have bought the stock before 28 April 2023. Payment date: 05 May 2023. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.5%).
Reported Earnings • Apr 02Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)Full year 2022 results: EPS: kr2.91. Revenue: kr3.23b (up 92% from FY 2021). Net income: kr394.0m (up 16% from FY 2021). Profit margin: 12% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Launched (during full year): 2 Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Feb 04Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)Full year 2022 results: EPS: kr2.91. Revenue: kr3.23b (up 92% from FY 2021). Net income: kr394.0m (up 16% from FY 2021). Profit margin: 12% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe.
공시 • Feb 02+ 1 more updateVitrolife AB (publ) Proposes Dividend for 2022Vitrolife AB (publ) proposed a dividend of SEK 0.85 per share for 2022 compared to SEK 0.80 per share a year ago, corresponding to SEK 115 million (SEK 108 million a year ago).
공시 • Feb 01Vitrolife AB (publ) Announces Executive ChangesVitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021)Third quarter 2022 results: EPS: kr0.80. Revenue: kr798.0m (up 97% from 3Q 2021). Net income: kr108.0m (up 3.5% from 3Q 2021). Profit margin: 14% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
공시 • Oct 27+ 3 more updatesVitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023Vitrolife AB (publ) announced that they will report first half, 2023 results on Jul 14, 2023
공시 • Oct 11Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced that the following people have been appointed as members of Vitrolife's election committee for the Annual General Meeting in 2023: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Erika Henriksson, appointed by EQT VIII; and Jón Sigurdsson, Chairman of the Board.
Valuation Update With 7 Day Price Move • Sep 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €17.23, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 26x in the Biotechs industry in Europe. Total returns to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.53 per share.
Buying Opportunity • Sep 23Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.7%. The fair value is estimated to be €23.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 4.2%. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 105% in the next 2 years.
공시 • Sep 13Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEOVitrolife AB (publ) announced that Thomas Axelsson, CEO of the company informed the Board of Directors of his desire and intention to retire and be released from his position. Consequently, the process to find a new CEO to replace Thomas will immediately begin and will be led by Jon Sigurdsson, Chairman of the Board. Thomas will remain as the CEO until the recruitment process is finalized.
Reported Earnings • Jul 17Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)Second quarter 2022 results: EPS: kr0.96 (up from kr0.79 in 2Q 2021). Revenue: kr829.0m (up 117% from 2Q 2021). Net income: kr130.0m (up 51% from 2Q 2021). Profit margin: 16% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 37%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
공시 • Jul 08Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023.
Recent Insider Transactions • May 04Chief Financial Officer recently bought €48k worth of stockOn the 29th of April, Patrik Tolf bought around 2k shares on-market at roughly €23.97 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)First quarter 2022 results: EPS: kr0.61 (down from kr1.09 in 1Q 2021). Revenue: kr752.0m (up 98% from 1Q 2021). Net income: kr82.0m (down 31% from 1Q 2021). Profit margin: 11% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 56%, compared to a 43% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 23First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)First quarter 2022 results: EPS: kr0.61 (down from kr1.09 in 1Q 2021). Revenue: kr752.0m (up 98% from 1Q 2021). Net income: kr82.0m (down 31% from 1Q 2021). Profit margin: 11% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 58%, compared to a 46% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Upcoming Dividend • Apr 21Upcoming dividend of kr0.80 per shareEligible shareholders must have bought the stock before 28 April 2022. Payment date: 04 May 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.9%). Lower than average of industry peers (1.4%).
공시 • Mar 29Vitrolife AB (Publ) Proposes DividendThe Board of Directors of Vitrolife AB (publ) proposed a dividend of SEK 0.80 per share and 29 April 2022 as the record day for the dividend, to its Annual General Meeting to be held on April 27, 2022.
Reported Earnings • Feb 17Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: kr2.97 (up from kr2.64 in FY 2020). Revenue: kr1.68b (up 35% from FY 2020). Net income: kr341.0m (up 19% from FY 2020). Profit margin: 20% (down from 23% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 94%, compared to a 59% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 16Vitrolife AB (Publ) Proposes DividendVitrolife AB (publ) proposed a dividend of SEK 108 million, corresponding to SEK 0.80 per share, compared to SEK 0.80 per share a year ago.
Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: kr405.6m (up 27% from 3Q 2020). Net income: kr104.3m (up 18% from 3Q 2020). Profit margin: 26% (down from 28% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 17Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr382.0m (up 83% from 2Q 2020). Net income: kr85.8m (up kr74.2m from 2Q 2020). Profit margin: 23% (up from 5.6% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Apr 29Vitrolife AB (publ) Approves Dividend for the Financial Year 2020At the Vitrolife AB (publ)’s Annual General Meeting held on April 28, 2021, the company approved dividend of SEK 0.80 per share for the financial year 2020. April 30, 2021 was adopted as the record day.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr379.0m (up 14% from 1Q 2020). Net income: kr118.2m (up 48% from 1Q 2020). Profit margin: 31% (up from 24% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Apr 22Upcoming dividend of kr0.80 per shareEligible shareholders must have bought the stock before 29 April 2021. Payment date: 05 May 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.5%).
Reported Earnings • Apr 01Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr1.25b (down 16% from FY 2019). Net income: kr286.8m (down 25% from FY 2019). Profit margin: 23% (down from 26% in FY 2019). The decrease in margin was driven by lower revenue. Post-clinical trial products Launched (during full year): 2 Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Feb 12Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: kr1.25b (down 16% from FY 2019). Net income: kr286.8m (down 25% from FY 2019). Profit margin: 23% (down from 26% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Feb 12Revenue misses expectationsRevenue missed analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 18%, compared to a 80% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Feb 03New 90-day high: €22.60The company is up 2.0% from its price of €22.20 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.49 per share.
공시 • Jan 22Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021Vitrolife AB (publ) announced that they will report fiscal year 2020 results at 8:00 AM, Central European Standard Time on Feb 10, 2021
Is New 90 Day High Low • Nov 16New 90-day low: €20.14The company is down 10.0% from its price of €22.46 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.55 per share.
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS kr0.81The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2020 results: Revenue: kr320.1m (down 15% from 3Q 2019). Net income: kr88.2m (down 17% from 3Q 2019). Profit margin: 28% (in line with 3Q 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectationsRevenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 12%, compared to a 321% growth forecast for the Biotechs industry in Germany.
공시 • Nov 07Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021Vitrolife AB (publ) announced that they will report fiscal year 2020 results at 6:46 AM, GMT Standard Time on Mar 30, 2021
공시 • Nov 06Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021Vitrolife AB (publ) announced that they will report Q1, 2021 results at 6:46 AM, GMT Standard Time on Apr 22, 2021